Skip to Main Content

Jessica Tuan

Assistant Professor of Medicine (Infectious Diseases); Affiliated Faculty, Yale Institute for Global Health; Associate Director, Yale Antivirals & Vaccines Research Program, Infectious Diseases

Research Summary

Dr. Tuan serves as a Principal Investigator for the following Yale School of Medicine research studies: 1) Evaluating Pitavastatin to Reduce Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE) (NIH/ACTG-funded clinical trial), 2) Pfizer mRNA Influenza vaccine clinical trial, 3) ACTG AIDS Clinical Trial Group STOMP Study: Trial of the Safety & Efficacy of Tecovirimat for Treatment of Human Monkeypox Virus Disease (Co-PI): 4) Qualitative Assessment of SARS-CoV-2 Immunogenicity (QUASI) after COVID-19 vaccination in People Living with HIV, 5) Outcomes of Pregnant Women Exposed to Sotrovimab for Treatment of COVID-19 in the Omicron Predominant Era (PRESTO).

She is a Sub-Investigator for the Yale Pfizer/BioNTech (adult, pediatric, booster) & Sanofi COVID-19 vaccine clinical trials. She is a Sub-Investigator for Yale School of Medicine HIV clinical trials: 1) Study to Assess the Effectiveness & Safety of Lenacapavir for HIV Pre-Exposure Prophylaxis (PURPOSE 2); 2) Evaluating the Safety & Efficacy of Bictegravir/Lenacapavir vs. Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens, 3) Study of Broadly Neutralizing Antibodies GS-5423 & GS-2872 in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1. Her other research focus is as a Sub-Investigator for the NIH/NIMH R21 grant "HIV PrEP Perspectives of Liberian Adolescent Girls & Young Women and their Providers," in collaboration with physicians at the John F. Kennedy Medical Center Hospital in Monrovia, Liberia.


Research Interests

HIV; Global Health; COVID-19

Selected Publications

Clinical Trials